Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 3
---
 We have launched                                                                                            
 a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating 
 the opioid crisis.                                                                                                                         |

| ● | Advancing Scientific Research: Our recent submissions                                                                          
 to and upcoming poster presentation at the American Society of Clinical Psychopharmacology’s 2025 Annual Meeting highlight our 
 commitment to innovative therapeutic strategies and groundbreaking research.                                                   |

Financial Resilience and Growth

We have fortified our financial foundation through
strategic initiatives:

Nasdaq & Strong Financial Position

| ● | We carry zero long-term debt, a rarity among biopharmaceutical                                                                       
 companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints. |

| ● | We raised approximately $4.2 million pursuant to private                                                                             
 placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private 
 placements has extended our operational runway to approximately 18 months.                                                           |

| ● | This financial stability empowers us to accelerate clinical                                      
 development, pursue strategic partnerships, and advance our innovative pipeline with confidence. |

<div align='center'>2</div>

Looking Ahead

The momentum generated by these developments underscores
our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology
landscape, driving NLS Pharmaceutics toward a future of unparalleled success.

As we embark on this exciting new chapter, we
remain laser-focused on:

✔ Building an international, strong, well-balanced
pipeline and top-notch biotechnology company

✔ Delivering life-changing therapies for
patients worldwide

✔ Expanding our pipeline through innovation
& strategic collaborations

✔ Maximizing shareholder value by maintaining
a strong financial position

We extend our deepest gratitude to our shareholders,
partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.

Sincerely,

Alex Zwyer

Chief Executive Officer

NLS Pharmaceutics (NASDAQ: NLSP)

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development
of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management team with a